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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and
related documents*
Section/item

Item
No

Description

Page Number

Administrative information
Title

1

Descriptive title identifying the study design, population,
interventions, and, if applicable, trial acronym

1

Trial registration

2a

Trial identifier and registry name. If not yet registered, name of
intended registry

4

2b

All items from the World Health Organization Trial Registration Data
Set

Protocol version

3

Date and version identifier

N/A

Funding

4

Sources and types of financial, material, and other support

7

Roles and
responsibilities

5a

Names, affiliations, and roles of protocol contributors

1

5b

Name and contact information for the trial sponsor

5c

Role of study sponsor and funders, if any, in study design;
25, Figure 1
collection, management, analysis, and interpretation of data; writing
of the report; and the decision to submit the report for publication,
including whether they will have ultimate authority over any of these
activities

5d

Composition, roles, and responsibilities of the coordinating centre,
steering committee, endpoint adjudication committee, data
management team, and other individuals or groups overseeing the
trial, if applicable (see Item 21a for data monitoring committee)

7,8,12, 13, 25, 28,
29

6a

Description of research question and justification for undertaking
the trial, including summary of relevant studies (published and

5-7

Introduction
Background and
rationale

unpublished) examining benefits and harms for each intervention

Objectives

6b

Explanation for choice of comparators

6-7

7

Specific objectives or hypotheses

8-10

1

Trial design

8

Description of trial design including type of trial (eg, parallel group,
crossover, factorial, single group), allocation ratio, and framework
(eg, superiority, equivalence, noninferiority, exploratory)

8

Methods: Participants, interventions, and outcomes
Study setting

9

Description of study settings (eg, community clinic, academic
hospital) and list of countries where data will be collected.
Reference to where list of study sites can be obtained

8

Eligibility criteria

10

Inclusion and exclusion criteria for participants. If applicable,
eligibility criteria for study centres and individuals who will perform
the interventions (eg, surgeons, psychotherapists)

16.17

Interventions

11a

Interventions for each group with sufficient detail to allow
replication, including how and when they will be administered

11,12

11b

Criteria for discontinuing or modifying allocated interventions for a
given trial participant (eg, drug dose change in response to harms,
participant request, or improving/worsening disease)

13, 15

11c

Strategies to improve adherence to intervention protocols, and any
procedures for monitoring adherence (eg, drug tablet return,
laboratory tests)

14,15

11d

Relevant concomitant care and interventions that are permitted or
prohibited during the trial

16,17, 21

Outcomes

12

Primary, secondary, and other outcomes, including the specific
9,10, 26-28
measurement variable (eg, systolic blood pressure), analysis metric
(eg, change from baseline, final value, time to event), method of
aggregation (eg, median, proportion), and time point for each
outcome. Explanation of the clinical relevance of chosen efficacy
and harm outcomes is strongly recommended

Participant timeline

13

Time schedule of enrolment, interventions (including any run-ins

15, Figure 2

and washouts), assessments, and visits for participants. A
schematic diagram is highly recommended (see Figure)
Sample size

14

Estimated number of participants needed to achieve study
objectives and how it was determined, including clinical and
statistical assumptions supporting any sample size calculations

15,16

Recruitment

15

Strategies for achieving adequate participant enrolment to reach
target sample size

18

Methods: Assignment of interventions (for controlled trials)
Allocation:

2

Sequence
generation

16a

Method of generating the allocation sequence (eg, computer11,12
generated random numbers), and list of any factors for stratification.
To reduce predictability of a random sequence, details of any
planned restriction (eg, blocking) should be provided in a separate
document that is unavailable to those who enrol participants or
assign interventions

Allocation
concealment
mechanism

16b

Mechanism of implementing the allocation sequence (eg, central
11,12
telephone; sequentially numbered, opaque, sealed envelopes),
describing any steps to conceal the sequence until interventions are
assigned

Implementation

16c

Who will generate the allocation sequence, who will enrol
participants, and who will assign participants to interventions

11,12

Blinding (masking)

17a

Who will be blinded after assignment to interventions (eg, trial
participants, care providers, outcome assessors, data analysts),
and how

12,13

17b

If blinded, circumstances under which unblinding is permissible, and 13
procedure for revealing a participant’s allocated intervention during
the trial

Methods: Data collection, management, and analysis
Data collection
methods

18a

Plans for assessment and collection of outcome, baseline, and
other trial data, including any related processes to promote data
quality (eg, duplicate measurements, training of assessors) and a
description of study instruments (eg, questionnaires, laboratory
tests) along with their reliability and validity, if known. Reference to
where data collection forms can be found, if not in the protocol

21-24

18b

Plans to promote participant retention and complete follow-up,
including list of any outcome data to be collected for participants

14,15

who discontinue or deviate from intervention protocols
Data management

19

Plans for data entry, coding, security, and storage, including any
related processes to promote data quality (eg, double data entry;

13

range checks for data values). Reference to where details of data
management procedures can be found, if not in the protocol
Statistical methods

20a

Statistical methods for analysing primary and secondary outcomes. 25-28
Reference to where other details of the statistical analysis plan can
be found, if not in the protocol

20b

Methods for any additional analyses (eg, subgroup and adjusted
analyses)

20c

Definition of analysis population relating to protocol non-adherence 15,16
(eg, as randomised analysis), and any statistical methods to handle
missing data (eg, multiple imputation)

25-28

3

Methods: Monitoring
Data monitoring

21a

Composition of data monitoring committee (DMC); summary of its
role and reporting structure; statement of whether it is independent
from the sponsor and competing interests; and reference to where
further details about its charter can be found, if not in the protocol.
Alternatively, an explanation of why a DMC is not needed

25, 28, Figure 1

21b

Description of any interim analyses and stopping guidelines,
including who will have access to these interim results and make
the final decision to terminate the trial

13

Harms

22

Plans for collecting, assessing, reporting, and managing solicited
and spontaneously reported adverse events and other unintended
effects of trial interventions or trial conduct

24,25

Auditing

23

Frequency and procedures for auditing trial conduct, if any, and
whether the process will be independent from investigators and the
sponsor

Ethics and dissemination
Research ethics
approval

24

Plans for seeking research ethics committee/institutional review
board (REC/IRB) approval

29,30

Protocol
amendments

25

Plans for communicating important protocol modifications (eg,
changes to eligibility criteria, outcomes, analyses) to relevant
parties (eg, investigators, REC/IRBs, trial participants, trial
registries, journals, regulators)

25,26

Consent or assent

26a

Who will obtain informed consent or assent from potential trial
participants or authorised surrogates, and how (see Item 32)

19, 30

26b

Additional consent provisions for collection and use of participant
data and biological specimens in ancillary studies, if applicable

Confidentiality

27

How personal information about potential and enrolled participants
will be collected, shared, and maintained in order to protect
confidentiality before, during, and after the trial

Declaration of
interests

28

Financial and other competing interests for principal investigators
for the overall trial and each study site

Access to data

29

Statement of who will have access to the final trial dataset, and

28

disclosure of contractual agreements that limit such access for
investigators
Ancillary and posttrial care

30

Provisions, if any, for ancillary and post-trial care, and for
compensation to those who suffer harm from trial participation

4

Dissemination
policy

31a

Plans for investigators and sponsor to communicate trial results to
participants, healthcare professionals, the public, and other relevant
groups (eg, via publication, reporting in results databases, or other
data sharing arrangements), including any publication restrictions

31b

Authorship eligibility guidelines and any intended use of
professional writers

31c

Plans, if any, for granting public access to the full protocol,
participant-level dataset, and statistical code

Informed consent
materials

32

Model consent form and other related documentation given to
participants and authorised surrogates

Biological
specimens

33

Plans for collection, laboratory evaluation, and storage of biological
specimens for genetic or molecular analysis in the current trial and
for future use in ancillary studies, if applicable

Appendices

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013
Explanation & Elaboration for important clarification on the items. Amendments to the
protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT
Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported”
license.
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